Catalyst
Slingshot members are tracking this event:
The FDA has set a Biosimilar User Fee Act target action date of Sept 14 2017 for ABP 215
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AMGN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 14, 2017
Occurred Source:
http://wwwext.amgen.com/media/news-releases/2017/09/fda-approves-amgen-and-allergans-mvasi-bevacizumabawwb-for-the-treatment-of-five-types-of-cancer/
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Abp 215, Bsufa, Bevacizumab
